List of Excipients in Branded Drug BRUKINSA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
BeOne Medicines USA Inc	BRUKINSA	zanubrutinib	72579-011	CELLULOSE, MICROCRYSTALLINE	2031-03-07
BeOne Medicines USA Inc	BRUKINSA	zanubrutinib	72579-011	CROSCARMELLOSE SODIUM	2031-03-07
BeOne Medicines USA Inc	BRUKINSA	zanubrutinib	72579-011	FERROSOFERRIC OXIDE	2031-03-07
BeOne Medicines USA Inc	BRUKINSA	zanubrutinib	72579-011	GELATIN	2031-03-07

BRUKINSA Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

BRUKINSA (zanubrutinib) uses a conventional immediate-release oral solid-dose formulation built around microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, colloidal silicon dioxide, magnesium stearate and color-coated gelatin capsules or tablets. The excipient estate is commercially accessible because the formulation relies on established compendial materials rather than a novel delivery system. The strongest opportunities are in generic or alternative-source manufacturing, excipient qualification, tablet conversion, capsule-shell substitution, supply-chain resilience and lower-cost regional production.

The main commercial constraint is not excipient exclusivity. It is the branded product’s active-ingredient, method-of-use and regulatory exclusivity position, together with the need to demonstrate pharmaceutical equivalence and bioequivalence for any ANDA or other follow-on product.

What excipients are used in BRUKINSA?

BRUKINSA is marketed in the United States as zanubrutinib capsules and tablets. The US prescribing information identifies conventional inactive ingredients for the oral dosage forms. Exact composition can vary by dosage form and market.

Component	Function in formulation	Commercial relevance
Microcrystalline cellulose	Diluent and dry-binding aid	Supports direct compression and robust tablet manufacture
Croscarmellose sodium	Superdisintegrant	Promotes rapid tablet or capsule-content disintegration
Povidone	Binder	Supports granule strength and content uniformity
Sodium lauryl sulfate	Wetting agent and surfactant	Improves wetting of the poorly water-soluble active ingredient
Colloidal silicon dioxide	Glidant and moisture-control aid	Improves powder flow and manufacturing consistency
Magnesium stearate	Lubricant	Controls ejection force and tooling behavior
Talc	Film-coating aid and anti-tacking agent	Supports coating uniformity
Titanium dioxide	Opacifier and pigment	Used in coating or capsule-shell appearance
Iron oxides	Colorants	Differentiate dosage forms and strengths
Polyvinyl alcohol	Film-forming coating polymer	Supports tablet coating
Polyethylene glycol, where used in the applicable coating system	Plasticizer	Improves coating flexibility
Gelatin	Capsule-shell material	Applies to the capsule presentation, not the tablet core

The label identifies the product as an immediate-release oral formulation rather than an extended-release, enteric-coated or lipid-based system. That limits formulation complexity but creates a clear performance requirement: the finished product must match the reference drug’s release behavior and demonstrate bioequivalence under the applicable FDA pathway. [1]

How do BRUKINSA capsules and tablets differ?

The capsule presentation uses a hard capsule shell with colorants and titanium dioxide. The tablet presentation uses a compressed core with a film coat. Both formats use broadly available pharmaceutical excipients.

The tablet format creates more opportunities for manufacturing optimization because suppliers can evaluate:

• Direct compression versus dry granulation.
• Alternative grades of microcrystalline cellulose.
• Different croscarmellose sodium particle-size distributions.
• Low-moisture excipient systems.
• Lower-level or alternative surfactants.
• Coating systems that reduce processing time.
• Pigment-free or reduced-color coating systems.

A follow-on manufacturer cannot assume that a technically acceptable substitute is commercially usable. Each excipient change must be assessed for dissolution, impurities, stability, process capability, packaging compatibility and bioequivalence risk.

What is the excipient strategy behind BRUKINSA?

The formulation strategy is conservative and manufacturable. It combines a conventional diluent-binder-disintegrant system with a wetting agent and standard lubricant. This approach is consistent with an immediate-release small-molecule product whose commercial priorities include reproducible manufacture, rapid scale-up and global supply.

Why is sodium lauryl sulfate commercially important?

Zanubrutinib has limited aqueous solubility. A surfactant such as sodium lauryl sulfate can improve wetting and reduce variability in dissolution testing. Its presence also creates a formulation-control point for follow-on products.

A change in surfactant type or concentration can affect:

• Apparent dissolution rate.
• Particle wetting.
• Drug-excipient interactions.
• Stability under heat and humidity.
• Gastrointestinal tolerability.
• Batch-to-batch release performance.

The surfactant is therefore a potential source of formulation differentiation, but it is not a straightforward opportunity for substitution. A lower-irritancy surfactant or alternative wetting system could support a differentiated product, yet any change would require formulation and bioequivalence work.

Why are microcrystalline cellulose and croscarmellose sodium important?

These materials form the mechanical and disintegration foundation of the dosage form. Microcrystalline cellulose contributes bulk and compactibility. Croscarmellose sodium promotes rapid breakup after ingestion.

For a generic manufacturer, grade selection can affect:

• Tablet tensile strength.
• Friability.
• Disintegration time.
• Dissolution profile.
• Compression speed.
• Ejection force.
• Weight variation.
• Sensitivity to lubricant overmixing.

For an excipient supplier, the opportunity is to sell a qualified grade with improved flow, lower moisture variability or better compactibility. The commercial value is more likely to come from process performance and supply reliability than from exclusivity.

What commercial opportunities exist for BRUKINSA excipients?

The largest opportunities fall into five categories: supply-chain replacement, generic formulation, process optimization, dosage-form differentiation and regional regulatory support.

Opportunity	Target customer	Value proposition	Main barrier
Dual-source excipients	BeiGene or contract manufacturers	Reduces dependence on one supplier	Change-control and comparability work
Direct-compression excipient packages	Generic manufacturers	Shortens processing and reduces equipment needs	Dissolution and mechanical-property matching
Low-moisture grades	API and finished-dose manufacturers	Improves stability and reduces hydrolysis risk	Higher cost and qualification burden
Alternative coating systems	Branded and generic manufacturers	Faster coating, lower solvent or pigment burden	Appearance and dissolution comparability
Animal-free capsule shells	Global manufacturers	Supports market access and patient preferences	Shell performance and regulatory documentation
Colorant-reduced products	Generic and specialty manufacturers	Simplifies regional compliance and branding	Strength differentiation and appearance
Co-processed excipients	Formulation developers	Improves flow, compression or disintegration	New material qualification
Regional excipient sourcing	Manufacturers outside the US	Reduces freight and supply risk	Local GMP and pharmacopoeial compliance
Packaging-excipient optimization	Product owners	Improves humidity protection and shelf life	Stability data and packaging change control

Which excipient suppliers are commercially relevant?

The relevant supplier classes include manufacturers of:

• Microcrystalline cellulose.
• Croscarmellose sodium.
• Povidone.
• Sodium lauryl sulfate.
• Colloidal silicon dioxide.
• Magnesium stearate.
• Film-coating systems.
• Pharmaceutical gelatin and vegetarian capsule shells.

Large global suppliers often compete on documentation, regulatory support, global manufacturing redundancy and technical service. Regional suppliers can compete on price and lead time. For BRUKINSA-related products, the most defensible supplier proposition is a validated, pharmacopeial grade supported by a strong change-notification program.

An excipient supplier should not position an alternative solely as a lower-price replacement. The better commercial package includes process data, impurity profiles, elemental impurity information, nitrosamine risk assessment, residual solvent data, microbiological controls and demonstrated performance in an immediate-release zanubrutinib-type formulation.

What formulation patents protect BRUKINSA?

The principal intellectual-property risk for BRUKINSA is expected to arise from zanubrutinib composition-of-matter protection, formulation or manufacturing claims, and method-of-use claims. The public US prescribing information does not establish that the listed excipients themselves are protected by a standalone excipient patent.

IP category	Relevance to BRUKINSA	Excipient opportunity
Zanubrutinib composition of matter	Core barrier to generic launch	Does not normally prevent independent excipient sourcing
Solid oral formulation claims	May cover specific excipient ratios or manufacturing parameters	Design-around may be possible, subject to claim scope
Crystalline or polymorph claims	Could affect API sourcing and finished-product development	Requires solid-state screening
Manufacturing-process claims	May cover crystallization, purification or drug-product processing	Alternative process development may reduce risk
Method-of-use claims	Cover treatment of hematologic malignancies	Relevant to labeling and Paragraph IV strategy
Packaging or stability claims	May protect moisture or degradation control	Creates opportunities for equivalent packaging systems

A formulation developer should search the USPTO, FDA Orange Book patent listings and relevant international registers for patents assigned to BeiGene or related entities. Patent status can differ by jurisdiction, patent family and terminal-disclaimer history. The absence of an excipient patent does not eliminate infringement risk if a claim covers the finished dosage form or a process using a particular excipient combination.

When does BRUKINSA lose exclusivity?

BRUKINSA was first approved in the United States on Nov. 14, 2019, for adult patients with Waldenstrom’s macroglobulinemia. FDA later expanded the label to include mantle cell lymphoma and marginal zone lymphoma. The product is a small molecule and is regulated through an NDA, not the biologics license application pathway. Biosimilar approval is therefore not the relevant follow-on mechanism. [2]

Regulatory milestone	Date or status
US NDA approval for Waldenstrom’s macroglobulinemia	Nov. 14, 2019
US approval for mantle cell lymphoma	Sept. 14, 2021
US approval for marginal zone lymphoma	Sept. 15, 2023
NDA pathway	505(b)(1) new drug application
Likely follow-on pathway	ANDA, subject to patent and exclusivity conditions
Biosimilar pathway	Not applicable
New chemical entity exclusivity	Generally five years from first approval, subject to statutory exceptions
Orphan-drug exclusivity	Applies only to qualifying indication-specific approvals and periods

The practical generic-entry date depends on the latest enforceable patent and any remaining indication-specific exclusivity. FDA regulatory exclusivity and patent exclusivity are separate. A five-year new chemical entity period may block an ANDA filing during the statutory period, while patent listings can delay approval after filing. Orphan-drug exclusivity may restrict approval for the same indication but does not automatically block all zanubrutinib products for all uses.

What is the Orange Book status of BRUKINSA?

BRUKINSA is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under the NDA for zanubrutinib. The relevant listing should be reviewed for:

• NDA number and dosage forms.
• Strengths and route of administration.
• Listed patents and use codes.
• Patent delisting or expiration updates.
• Whether capsule and tablet presentations are listed separately.
• Any reference-listed-drug status relevant to an ANDA.

The Orange Book is the controlling public source for FDA-listed patents and use codes. Commercial decisions should not rely only on a product label or a patent-family database because Orange Book listings can change through certifications, corrections, litigation outcomes and regulatory updates. [3]

Which companies are challenging BRUKINSA?

The most relevant challengers are likely to be generic pharmaceutical companies pursuing zanubrutinib ANDAs rather than biosimilar developers. Public commercial visibility into individual ANDA applicants can remain limited until a Paragraph IV notice, patent litigation complaint or FDA approval becomes public.

A Paragraph IV challenge would assert that one or more listed patents are invalid, unenforceable or not infringed. The reference-product sponsor generally has 45 days after receiving notice to file an infringement action. A timely suit can trigger a 30-month stay of FDA approval, subject to statutory exceptions and litigation developments. [4]

Potential generic strategies include:

1. A Paragraph III filing accepting the listed patent expiry date.
2. A Paragraph IV filing challenging composition, formulation or method-of-use patents.
3. A section viii statement carving out patented indications.
4. A later-filed ANDA timed to commercial entry after the relevant exclusivity period.

What patent litigation affects BRUKINSA?

The litigation risk should be separated into three layers:

API and composition claims

These claims usually present the largest barrier because an ANDA applicant cannot avoid using zanubrutinib while still making the same drug product. A successful challenge or expiry of the relevant composition patent can materially change the entry timetable.

Formulation and dosage-form claims

These claims are more relevant to excipient strategy. A generic company may design around a claim by changing excipient identity, concentration, granulation method, coating system or capsule presentation. Design-around analysis must compare the actual claim limitations, not simply the ingredient list.

Method-of-use claims

BRUKINSA has multiple hematologic indications. A generic company may attempt a skinny label that excludes patented uses. That approach can reduce some infringement exposure but does not eliminate inducement or contributory-infringement risk if marketing materials, distributor behavior or clinical use support the patented indication.

How strong is the BRUKINSA patent estate?

The estate is strongest where claims protect zanubrutinib itself or essential manufacturing steps. Excipient-only protection appears less central to the product’s commercial defense. A conventional excipient system generally lowers the technical barrier to generic development, although it does not eliminate legal or regulatory barriers.

Estate element	Relative barrier	Implication
Active-ingredient patents	High	Most important to launch timing
API manufacturing patents	Medium to high	Can affect cost and independent supply
Solid-state and polymorph patents	Medium	Requires API characterization
Formulation patents	Low to medium	Potential design-around area
Method-of-use patents	Medium	Affects labeling and litigation
Excipient patents	Low based on public label	Limited standalone barrier
Trade secrets and process know-how	Medium	May affect yield and scale-up

Patent strength also depends on claim breadth, prosecution history, validity defenses, written-description support, prior art, ownership, maintenance fees and terminal-disclaimer dates. No single expiration date should be treated as the complete commercial loss-of-exclusivity date.

What manufacturing and IP barriers exist for BRUKINSA alternatives?

A follow-on manufacturer must address more than excipient identity. Critical development work includes:

• API particle size and polymorph control.
• Drug-excipient compatibility.
• Blend uniformity at low drug load.
• Lubrication time and magnesium stearate sensitivity.
• Dissolution across pH conditions.
• Stability under accelerated and long-term storage.
• Coating uniformity and strength identification.
• Capsule-shell or tablet-swallowability requirements.
• Nitrosamine and elemental impurity controls.
• Container-closure moisture protection.
• Process validation at commercial scale.

A conventional formulation can still be difficult to copy if the active has challenging powder properties, narrow dissolution margins or sensitivity to moisture and surfactant level.

How does BRUKINSA compare with competing BTK inhibitors?

BRUKINSA competes with IMBRUVICA (ibrutinib) and CALQUENCE (acalabrutinib), which are also small-molecule Bruton tyrosine kinase inhibitors. The competitive landscape affects excipient opportunities because generic developers may prioritize the product with the shortest remaining patent barrier and the simplest dosage form.

Product	Active ingredient	Dosage-form profile	Follow-on relevance
BRUKINSA	Zanubrutinib	Capsules and tablets	Excipient substitution and tablet development
IMBRUVICA	Ibrutinib	Capsules, tablets and oral suspension in certain markets	More dosage-form and indication complexity
CALQUENCE	Acalabrutinib	Tablets and capsules	Formulation and acid-modification considerations

BRUKINSA’s conventional solid-dose design may make excipient benchmarking easier than products requiring complex release systems. That advantage can be offset by the strength of zanubrutinib patent claims and the size of the treated patient population.

What revenue exposure creates commercial opportunity?

BRUKINSA has become a major commercial product for BeiGene and is distributed across multiple markets. Revenue exposure creates demand for dependable excipient supply, global manufacturing qualification and capacity reservation. The most valuable opportunities are likely to involve supply continuity rather than a single replacement excipient.

Potential commercial targets include:

• Global contract development and manufacturing organizations.
• Regional generic manufacturers.
• Excipient distributors with regulatory support.
• Film-coating suppliers.
• Capsule-shell manufacturers.
• Packaging suppliers focused on moisture control.
• Analytical laboratories supporting dissolution and stability comparability.

The commercial case is strongest when a supplier can support both US ANDA development and international submissions. A single excipient change may require separate regulatory assessments across FDA, EMA and other national agencies.

Key Takeaways

• BRUKINSA uses a conventional immediate-release oral solid-dose excipient system.
• Microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, colloidal silicon dioxide and magnesium stearate are central formulation components.
• The product is a small molecule, so generic competition would proceed through ANDA mechanisms, not biosimilar pathways.
• The principal exclusivity barriers are expected to involve zanubrutinib patents, manufacturing claims and method-of-use claims rather than standalone excipient patents.
• The best excipient opportunities are dual sourcing, lower-moisture grades, direct-compression systems, coating optimization, capsule-shell alternatives and regional supply.
• Generic developers must assess formulation patents and process claims before changing excipient identity or concentration.
• FDA Orange Book data and current patent litigation records control launch-timing analysis.

FAQs

Can a generic manufacturer use different excipients from BRUKINSA?

Yes. An ANDA applicant generally may use different inactive ingredients if the product remains pharmaceutically equivalent, meets applicable regulatory requirements and demonstrates bioequivalence. The change cannot create unacceptable safety, quality or performance differences.

Is sodium lauryl sulfate essential to BRUKINSA bioequivalence?

It may be important to the reference product’s wetting and dissolution behavior, but the label alone does not establish that it is indispensable. A substitute wetting system would require comparative formulation, dissolution, stability and bioequivalence evaluation.

Does BRUKINSA have biosimilar competition risk?

No. Zanubrutinib is a small-molecule drug approved under an NDA. Competitive follow-on products would generally be generics or other 505(b) applications, not biosimilars.

Can a vegetarian capsule replace the BRUKINSA gelatin capsule?

Potentially, but the shell change would require assessment of mechanical strength, moisture transfer, dissolution, stability, appearance and regulatory acceptability. Hydroxypropyl methylcellulose capsules are a common alternative, but they are not automatically equivalent in performance.

Are BRUKINSA excipients likely to create a standalone patent barrier?

The listed excipients are standard pharmaceutical materials. The stronger risk generally lies in patents covering zanubrutinib, solid-state forms, drug-product composition, manufacturing processes or therapeutic uses.

References

1. U.S. Food and Drug Administration. (2024). BRUKINSA (zanubrutinib) prescribing information. BeiGene USA, Inc. https://www.accessdata.fda.gov
2. U.S. Food and Drug Administration. (2019). FDA approves zanubrutinib for adult patients with mantle cell lymphoma and Waldenstrom’s macroglobulinemia. https://www.fda.gov
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
4. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j). https://uscode.house.gov